CD274 and breast cancer: The efficacy of CD44v6 CARs was evaluated using 3D TNBC tumor spheroid models and Jurkat reporter cells, demonstrating significant tumor cell lysis, particularly in the presence of high PD-L1 expression, a common feature in BC cell lines [233].